Next Article in Journal
STAT3: An Anti-Invasive Factor in Colorectal Cancer?
Previous Article in Journal
Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
Previous Article in Special Issue
The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer
Cancers 2014, 6(3), 1382-1393; doi:10.3390/cancers6031382
Article

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus

1
,
1
,
2
,
3
 and
4,*
1 Institute of Pathology, Technische Universität München, München 81765, Germany 2 Department of Surgery, Klinikum Rechts der Isar der Technischen Universität München, München 81622, Germany 3 Institute of Pathology, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg 85764, Germany 4 Institute of Pathology, University of Bern, Bern 3010, Switzerland
* Author to whom correspondence should be addressed.
Received: 16 January 2014 / Revised: 25 April 2014 / Accepted: 16 June 2014 / Published: 27 June 2014
(This article belongs to the Special Issue Heat Shock Proteins in Cancer: Chaperones of Tumorigenesis)
View Full-Text   |   Download PDF [1177 KB, uploaded 27 June 2014]   |  

Abstract

Her2 overexpression and amplification can be found in a significant subset of esophageal adenocarcinomas. The activity of Her2 has been shown to be modulated by molecular chaperones such as HSP90. We analyzed expression/amplification data for HSP90 and Her2 on 127 primary resected esophageal adenocarcinomas in order to evaluate a possible relationship between these two molecules. HSP90 expression determined by immunohistochemistry was observed in various levels. Thirty nine (39) tumors (30.7%) were classified as Her2-positive according to their immunoreactivity and amplification status. There was a significant correlation between HSP90 expression and Her2-status (p = 0.008). This could also be demonstrated by quantitative protein expression analysis with reverse phase protein arrays (r = 0.9; p < 0.001). Her2-status was associated withpT-category (p = 0.041), lymph node metastases (p = 0.049) and tumor differentiation (p = 0.036) with a higher percentage of cases with negative Her2 status in lower tumor stagesA negative Her2-status was also associated with better survival in univariate and multivariate analysis (p = 0.001 and p = 0.014). For HSP90, no associations between clinical and pathological parameters were found. The observed association between HSP90 expression and Her2 suggests a co-regulation of these molecules in at least a subset of esophageal adenocarcinomas. Anti-HSP90 drugs, which recently have been introduced in cancer treatment, may also be an option for these tumors by targeting HSP90 alone or in combination with Her2.
Keywords: HSP90; Her2; esophageal adenocarcinoma; immunohistochemistry; RPPA; in situ hybridization HSP90; Her2; esophageal adenocarcinoma; immunohistochemistry; RPPA; in situ hybridization
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Slotta-Huspenina, J.; Becker, K.-F.; Feith, M.; Walch, A.; Langer, R. Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus. Cancers 2014, 6, 1382-1393.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert